In vivo combination therapy of EGFR-specific CAR T cells with the CDK7 inhibitor THZ1 showed a suppression of immune resistance, tumor growth, and metastasis in triple-negative breast cancer models [112]. This evidence concerns the gene EGFR and triple-negative breast carcinoma.